SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
To keep up to date with news from this category use our
IRONWOOD AND ASTELLAS ANNOUNCE JAPAN LICENSING AGREEMENT FOR LINACLOTIDE
CAMBRIDGE, Mass. and TOKYO, Japan, November 10, 2009-- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and...
New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting
November 04, 2009 -- Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Strasbourg, France, November, 4th, 2009 - Transgene S.A. (Euronext Paris: FR0005175080) today announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical...
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
CAMBRIDGE, Mass.-- November 3, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9...
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today...
IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION
CAMBRIDGE, Mass. and New York, November 2, 2009 -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top line results from two Phase 3 clinical trials assessing the safety...
ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST
RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho) positive fetal red blood...
Movetis obtains EU authorisation for the commercialisation of Resolor
Turnhout, October 22, 2009 Movetis, the GI specialty pharmaceutical company based in Belgium, announces that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor...
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
FOSTER CITY, CA, Oct 21, 2009 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient at the Atlanta Gastroenterology Associates in Atlanta, GA, in a phase 2 trial of SCV-07...
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway
Oslo, Norway, 27 August 2009--Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received a government grant of up to USD 1.1 mill (NOK 6.9 mill) to accelerate the Phase II clinical programme with Intravenous...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
